Effect of Irbesartan on Endothelial Function of the Retinal Vasculature in Patients With Hypercholesterolemia

This study has been completed.

Sponsor:

Collaborator:

Bristol-Myers Squibb

Information provided by (Responsible Party):

Roland E. Schmieder, University of Erlangen-Nürnberg Medical School

ClinicalTrials.gov Identifier:

NCT00152698

First received: September 8, 2005

Last updated: January 18, 2013

Last verified: January 2013

History of Changes

Purpose

The retinal vasculature is morphologically and functionally related to the cerebral vessels due to its common origin from the internal carotid artery. A recent study demonstrated that endothelium-dependent vasodilation of the retinal vasculature is impaired in patients with essential hypertension, which is a strong risk factor for stroke. Furthermore, AT1-receptor blockade was demonstrated to improve retinal endothelium-dependent vasodilation in these hypertensive patients. Hypercholesterolemia is also a risk factor for ischemic stroke and impairment of endothelial function has been observed in various vascular beds in hypercholesterolemic patients, including the coronary and the forearm vasculature. Whether endothelial function of the retinal vasculature is impaired in patients with hypercholesterolemia has not yet been investigated. In patients with stroke, AT1-receptor blockade and angiotensin-converting enzyme inhibition have beneficial effects on clinical outcome. Alterations of endothelial function of the cerebral vasculature might be one pathogenetic factor for the beneficial clinical outcome. To further address this issue, the present study was designed to test the hypothesis that endothelium-dependent vasodilation of the retinal vasculature is impaired in hypercholesterolemic patients and that endothelial function can be improved by AT1-receptor blockade.

Condition	Intervention	Phase
Hypercholesterolemia	Drug: Irbesartan	Phase 3


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Crossover Assignment Masking: Double (Participant, Investigator) Primary Purpose: Treatment
Official Title:	A Randomised, Double-blind, Placebo-controlled, Phase III Trial to Study the Effect of Irbesartan on Endothelial Function of the Retinal Vasculature in Patients With Hypercholesterolemia

Resource links provided by NLM:

MedlinePlus related topics: Cholesterol

Drug Information available for: Irbesartan

U.S. FDA Resources

Further study details as provided by Roland E. Schmieder, University of Erlangen-Nürnberg Medical School:

Primary Outcome Measures:

Comparison of retinal endothelial function between hypercholesterolemic patients and healthy control subjects

Secondary Outcome Measures:

Effect of AT1-receptor blockade on retinal endothelial function in hypercholesterolemic patients


Estimated Enrollment:	80
Study Start Date:	November 2009
Study Completion Date:	December 2009
Primary Completion Date:	December 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Active Comparator: Irbesartan	Drug: Irbesartan
Placebo Comparator: Placebo

Detailed Description:

see above

Eligibility


Ages Eligible for Study:	18 Years to 65 Years (Adult)
Sexes Eligible for Study:	Male
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Male patients aged 18-65 years with LDL-cholesterol >= 130mg/dl
Male healthy control subjects aged 18-65 years

Exclusion Criteria:

All kinds of secondary hyperlipidemia.
Advanced damage of vital organs (grades III and IV retinopathy)
Lipid-lowering drugs (including lipid lowering dietary supplements or food additives) within the last 4 weeks
History of serious hypersensitivity reaction to AT1-receptor blockers
Actual or anamnestic alcohol- or drug abuse.
Smokers or ex-smokers < 1 year.
Patients with Diabetes mellitus (oral medication or insulin).
Patients with arterial fibrillation or AV-Block (II° or more).
Patients with anamnestic myocardial infarction.
Patients with instable angina pectoris including EcG-aberrations or cardiac insufficiency NYHA III or IV.
History of malignancy (unless a documented disease-free period exceeding 10 years is present) with the exception of basal cell carcinoma of the skin
History of allograft transplantation
Patients with anaphylaxis or known therapy resistance of the used test matters
Therapy with not approved concomitant medication, or participation in a clinical study within 4 weeks preceding treatment start.
Disease which interfere with the pharmacodynamics and pharmacokinetics of the study drug.
Liver or kidney disease with SGOT, GPT, g-GT, AP, bilirubin and creatinin above 200% of standard.
Patients, who are not sufficiently compliant, or patients, who are not capable or willing to appear for controlling visits.
Presumed risk of transmission of HIV or hepatitis via blood from the proband

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00152698

Locations


Germany
CRC, Medizinsiche Klinik 4, Nephrology and Hypertension, University of Erlangen-Nürnberg
Erlangen, Bavaria, Germany, 91054

Sponsors and Collaborators

University of Erlangen-Nürnberg Medical School

Bristol-Myers Squibb

Investigators


Principal Investigator:	Roland E Schmieder, MD	CRC, Medizinische Klinik 4, Nephrology and Hypertension, University of Erlangen-Nürnberg

More Information


Responsible Party:	Roland E. Schmieder, Prof. Dr. med., University of Erlangen-Nürnberg Medical School
ClinicalTrials.gov Identifier:	NCT00152698 History of Changes
Other Study ID Numbers:	Retina-Irbesartan
Study First Received:	September 8, 2005
Last Updated:	January 18, 2013

Additional relevant MeSH terms:


Hypercholesterolemia Hyperlipidemias Dyslipidemias Lipid Metabolism Disorders Metabolic Diseases	Irbesartan Antihypertensive Agents Angiotensin II Type 1 Receptor Blockers Angiotensin Receptor Antagonists Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on August 18, 2017

To Top